Co-Authors
This is a "connection" page, showing publications co-authored by Bart Haagmans and Frank van Kuppeveld.
Connection Strength
0.612
-
SARS-CoV-2 Neutralizing Human Antibodies Protect Against Lower Respiratory Tract Disease in a Hamster Model. J Infect Dis. 2021 06 15; 223(12):2020-2028.
Score: 0.238
-
A conserved immunogenic and vulnerable site on the coronavirus spike protein delineated by cross-reactive monoclonal antibodies. Nat Commun. 2021 03 17; 12(1):1715.
Score: 0.058
-
Publisher Correction: A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020 05 14; 11(1):2511.
Score: 0.055
-
A human monoclonal antibody blocking SARS-CoV-2 infection. Nat Commun. 2020 05 04; 11(1):2251.
Score: 0.055
-
Towards a solution to MERS: protective human monoclonal antibodies targeting different domains and functions of the MERS-coronavirus spike glycoprotein. Emerg Microbes Infect. 2019; 8(1):516-530.
Score: 0.050
-
Identification of sialic acid-binding function for the Middle East respiratory syndrome coronavirus spike glycoprotein. Proc Natl Acad Sci U S A. 2017 10 03; 114(40):E8508-E8517.
Score: 0.046
-
ATP1A1-mediated Src signaling inhibits coronavirus entry into host cells. J Virol. 2015 Apr; 89(8):4434-48.
Score: 0.038
-
Coronavirus cell entry occurs through the endo-/lysosomal pathway in a proteolysis-dependent manner. PLoS Pathog. 2014 Nov; 10(11):e1004502.
Score: 0.038
-
The receptor binding domain of the new Middle East respiratory syndrome coronavirus maps to a 231-residue region in the spike protein that efficiently elicits neutralizing antibodies. J Virol. 2013 Aug; 87(16):9379-83.
Score: 0.034